New, Existing Players See Opportunity In Crowded Contraceptive Space
With the notable exceptions of Bayer and Johnson & Johnson, big pharma generally does not participate in the contraceptive market. (Merck and Pfizer also are in the market, although their participation occurs on a smaller scale and largely outside the U.S.)
You may also be interested in...
The upcoming Therapeutic Area Partnership conference will showcase companies in niche areas that are prime targets for partnerships or acquisitions.
Oral contraceptive market is highly genericized and safety-conscious. A new indication for Natazia in heavy menstrual bleeding, however, could hold appeal compared to more invasive treatment options.
Some patients in an FDA-funded study had less risk for blood clots than others and finding the reason is a subject for future studies, several members of an advisory panel told FDA Dec. 9. The Reproductive Health Drugs and Drug Safety and Risk Management Committees concluded in a 19-5 vote that the drug’s benefits outweigh its risks.